{"doi":"10.1002/pbc.28929","title":"Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group","abstract":"The 5-year disease-free survival (DFS) of National Cancer Institute (NCI) high-risk (HR) B-lymphoblastic leukemia (B-ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation (EOC) MRD ≥0.01% is 39 ± 7%, warranting consideration of hematopoietic stem cell transplant (HSCT). However, the impact of EOC MRD in NCI standard-risk (SR) B-ALL patients using COG regimens is unknown. We found that SR patients with MRD ≥0.01% at both EOI and EOC have a 4-year DFS/overall survival (OS) of 72.9 ± 19.0%/91.7 ± 10.8% versus 90.7 ± 2.9%/95.5 ± 2.0% (p = .0019/.25) for those with EOI MRD ≥0.01% and EOC MRD <0.01%. These data suggest that routine use of HSCT may not be warranted in EOC MRD ≥0.01% SR patients.","journal":"Pediatric Blood & Cancer","year":2021,"id":190593,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9594,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":395546,"name":"Yunfeng Dai","orcid":"0000-0003-3961-4766","position":1,"is_corresponding":false},{"id":355165,"name":"Meenakshi Devidas","orcid":"0000-0002-1099-3478","position":2,"is_corresponding":false},{"id":247452,"name":"Karen R. Rabin","orcid":"0000-0002-4081-8195","position":3,"is_corresponding":false},{"id":501660,"name":"Patrick A. Zweidler‐McKay","orcid":"0000-0001-6621-523X","position":4,"is_corresponding":false},{"id":561180,"name":"Anne Angiolillo","orcid":null,"position":5,"is_corresponding":false},{"id":560384,"name":"Reuven J. Schore","orcid":"0000-0002-1582-2168","position":6,"is_corresponding":false},{"id":560382,"name":"Michael J. Burke","orcid":"0000-0001-6626-2773","position":7,"is_corresponding":false},{"id":560383,"name":"Wanda L. Salzer","orcid":"0000-0002-7820-9635","position":8,"is_corresponding":false},{"id":252809,"name":"Nyla A. Heerema","orcid":null,"position":9,"is_corresponding":false},{"id":295289,"name":"Andrew J. Carroll","orcid":"0000-0001-9844-730X","position":10,"is_corresponding":false},{"id":355167,"name":"Naomi Winick","orcid":"0000-0002-6636-3870","position":11,"is_corresponding":false},{"id":301503,"name":"Stephen P. Hunger","orcid":"0000-0002-5492-3957","position":12,"is_corresponding":false},{"id":271728,"name":"Elizabeth A. Raetz","orcid":"0000-0002-8547-1658","position":13,"is_corresponding":false},{"id":301504,"name":"Mignon L. Loh","orcid":"0000-0003-4099-4700","position":14,"is_corresponding":false},{"id":355168,"name":"Brent L. Wood","orcid":"0000-0001-7414-3969","position":15,"is_corresponding":false},{"id":357126,"name":"Michael J. Borowitz","orcid":null,"position":16,"is_corresponding":false},{"id":535218,"name":"Rachel E. Rau","orcid":"0000-0003-4096-6603","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-18T23:49:26.966524Z","pmid":"33559396","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}